These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29854396)

  • 1. Switching and augmentation strategies for antipsychotic medications in acute-phase schizophrenia: latest evidence and place in therapy.
    Hatta K; Sugiyama N; Ito H
    Ther Adv Psychopharmacol; 2018 Jun; 8(6):173-183. PubMed ID: 29854396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipsychotic switching versus augmentation among early non-responders to risperidone or olanzapine in acute-phase schizophrenia.
    Hatta K; Otachi T; Fujita K; Morikawa F; Ito S; Tomiyama H; Abe T; Sudo Y; Takebayashi H; Yamashita T; Katayama S; Nakase R; Shirai Y; Usui C; Nakamura H; Ito H; Hirata T; Sawa Y;
    Schizophr Res; 2014 Sep; 158(1-3):213-22. PubMed ID: 25086659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical pharmacotherapy for acute schizophrenia patients.
    Hatta K
    Psychiatry Clin Neurosci; 2015 Nov; 69(11):674-85. PubMed ID: 26037685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for Early Non-response to Antipsychotic Drugs in the Treatment of Acute-phase Schizophrenia.
    Hatta K; Ito H
    Clin Psychopharmacol Neurosci; 2014 Apr; 12(1):1-7. PubMed ID: 24851115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
    Stahl SM; Grady MM
    Curr Med Chem; 2004 Feb; 11(3):313-27. PubMed ID: 14965234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.
    Tundo A; de Filippis R; Proietti L
    World J Psychiatry; 2015 Sep; 5(3):330-41. PubMed ID: 26425446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H; Nyhuis AW; Faries DE; Kinon BJ; Baker RW; Shekhar A
    Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching.
    Agid O; Schulze L; Arenovich T; Sajeev G; McDonald K; Foussias G; Fervaha G; Remington G
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1017-22. PubMed ID: 23706529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of antipsychotic monotherapy and polytherapy in 1543 patients with acute-phase schizophrenia.
    Hatta K; Hasegawa H; Imai A; Sudo Y; Morikawa F; Katayama S; Watanabe H; Ishizuka T; Nakamura M; Misawa F; Fujita K; Ozaki S; Umeda K; Nakamura H; Sawa Y; Sugiyama N;
    Asian J Psychiatr; 2019 Feb; 40():82-87. PubMed ID: 30772732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maximizing response to first-line antipsychotics in schizophrenia: a review focused on finding from meta-analysis.
    Smith RC; Leucht S; Davis JM
    Psychopharmacology (Berl); 2019 Feb; 236(2):545-559. PubMed ID: 30506237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone.
    Suzuki T; Uchida H; Watanabe K; Nakajima S; Nomura K; Takeuchi H; Tanabe A; Yagi G; Kashima H
    Hum Psychopharmacol; 2008 Aug; 23(6):455-63. PubMed ID: 18537222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Acceptability, and Tolerability of Antipsychotics in Treatment-Resistant Schizophrenia: A Network Meta-analysis.
    Samara MT; Dold M; Gianatsi M; Nikolakopoulou A; Helfer B; Salanti G; Leucht S
    JAMA Psychiatry; 2016 Mar; 73(3):199-210. PubMed ID: 26842482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
    Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
    J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between augmentation with olanzapine and increased risperidone dose in acute schizophrenia patients showing early non-response to risperidone.
    Hatta K; Otachi T; Sudo Y; Kuga H; Takebayashi H; Hayashi H; Ishii R; Kasuya M; Hayakawa T; Morikawa F; Hata K; Nakamura M; Usui C; Nakamura H; Hirata T; Sawa Y;
    Psychiatry Res; 2012 Jul; 198(2):194-201. PubMed ID: 22421064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of switching antipsychotic medications.
    Essock SM; Covell NH; Davis SM; Stroup TS; Rosenheck RA; Lieberman JA
    Am J Psychiatry; 2006 Dec; 163(12):2090-5. PubMed ID: 17151159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia.
    Faries DE; Ascher-Svanum H; Nyhuis AW; Kinon BJ
    Curr Med Res Opin; 2008 May; 24(5):1399-405. PubMed ID: 18397549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of atypical antipsychotic medications on the use of health care by patients with schizophrenia.
    Chen L; McCombs JS; Park J
    Value Health; 2008; 11(1):34-43. PubMed ID: 18237358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
    Ritchie CW; Chiu E; Harrigan S; Hall K; Hassett A; Macfarlane S; Mastwyk M; O'Connor DW; Opie J; Ames D
    Int J Geriatr Psychiatry; 2003 May; 18(5):432-40. PubMed ID: 12766921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.